11th Annual Managed Markets and Account Management Strategies Conference

September 18-19, 2019 | New Orleans, LA

Doubletree by Hilton New Orleans Hotel

Download AgendaRegister Now

DAY TWO | THURSDAY, SEPTEMBER 19

8:30 REGISTRATION & WELCOME COFFEE

8:55 OPENING REMARKS

TRACKED BOARDROOM STYLE SESSIONS

TRACK ONE

9:00 LAUNCHING MANAGED MARKET OPERATIONS FOR START UP ORGANIZATIONS

  • Conducting market analysis for intended therapy
  • Parameters for internal resource allocation
  • Implementing KOL/MSL recruitment processes
  • Building account management field teams

Lesly Charanza, HERON THERAPEUTICS

 

9:45 RECOGNIZING THE IMPORTANCE FOR INCREASED ENGAGEMENT WITH IDN STAKEHOLDERS

  • Building support of product access within IDN networks
  • Strategies employed by IDNs to stabilize costs & impact on access
    • Prescribing standardization
    • Outcomes tracking
  • Understanding the changes in IDN and PBM relationships

Josh Rich, KALA PHARMACEUTICALS

TRACK TWO

9:00 PROPOSED IMPLEMENTATION OF INTERNATIONAL REFERENCE PRICING IN THE U.S.

  • Product impacted by proposed IRP model
  • Economic outcomes of IRP adoption in the U.S.
    • Medicare/Medicaid spend
    • Commercial coverage
  • Exploring IRP influence where currently utilized
  • Challenges of IRP on setting realistic pricing ranges

Neal Rafferty, Director, National Accounts – Managed Markets
MERZ PHARMACEUTICALS

 

9:45 PROPOSED CHANGES TO MEDICAID VALUE BASED PROGRAMS

  • Exploring state proposed plans regarding governmental VBCs
  • Data analysis requirements for Medicaid value contracts
    • Patient population characteristics
    • Treatment outcomes
  • Importance of state payer and manufacturer partnership
  • Forecasting future implementation of Medicaid changes

Jessica Ridlen, JAZZ PHARMACEUTICALS

10:30 COFFEE AND NETWORKING BREAK

11:00 UTILIZING EFFECTIVE ENGAGEMENT TACTICS FOR REGIONAL CUSTOMERS

  • Benefits of strong regional customer engagement
  • Tailoring communication based on regional market needs
  • Leveraging national contacts to connect with regional leaders

Terry Ahlers, BAYER

 

11:45 CHANGES & TRENDS IN COVERAGE REVIEW MEETINGS

  • Aligning meeting timeline with prepared agenda
  • Strategies to ensure positive review outcomes
  • Message development for clinical review meetings
  • Trends regarding tone and expectations from reviews

Joanne Chia, SANOFI GENZYME

11:00 INNOVATIVE CONTRACTING MODELS FOR INCREASED MARKET ACCESS

  • Complexities of indication based contracting models
  • Assessments to determine appropriate contracting strategy
  • Elements of outcomes-based contracting operations
  • Non-traditional payment models for innovative products

Rob Laverty, BRAEBURN PHARMACEUTICALS

 

11:45 ANALYSIS OF CURRENT VALUE BASED CONTRACTS

    • Outcomes of recent value based contracts
    • Regulatory considerations impacting VBCs
    • Industry expectations for value based agreements
  • Quality & financial incentives of value based contracts
  • Analytics and reporting processes for VBCs

Sean Quinn, HIGHMARK

12:30 LUNCHEON FOR ALL SPEAKERS, SPONSORS AND ATTENDEES

1:45 THERAPEUTIC SPOTLIGHT: OFFICE ADMINISTERED PRODUCT MANAGED MARKETS PROCESSES

  • Office administered vs. pharmacy product coverage
  • Tracking outcomes of office administered therapies
  • Applicable coverage and contracting models
  • Trends in Medicare & Medicaid coverage

Rachel Wade, GLAXOSMITHKLINE

1:45 OPPORTUNITIES FOR USING RWE TO SHAPE EFFECTIVE MARKET ACCESS STRATEGIES

  • Showcasing the product and patient journey
    • Patient population numbers
    • Treatment strategies
    • Product outcomes
  • Analyses of product performance in competitive markets
  • Providing real-time responses to payer & HCP questions

Lisa Strouss, TRIS PHARMACEUTICALS

2:30 MAXIMIZING FACE-TO-FACE MEETINGS WITH MCO REPRESENTATIVES

  • Impactful product data & materials utilized in MCO meetings
  • Determining product team representatives to have present
  • Compliance considerations for MCO meeting interactions
  • Trends in information requests and expectations from MCOs

Richard Wardrop, ALDER BIOPHARMACEUTICALS

 

3:15 COFFEE AND NETWORKING BREAK